IMX has "news" out...
Press Release Source: Implant Sciences Corporation
Implant Sciences Provides Progress Reports on the 'Quantum Sniffer'
Thursday May 29, 9:47 am ET
CEO Interviewed by Newsweek Radio, Boston Business Journal and Washington D.C.'s WRC-TV
WAKEFIELD, Mass.--(BUSINESS WIRE)--May 29, 2003--Implant Sciences Corporation's (AMEX: "IMX," IMX.WS"), President and CEO, Dr. Anthony J. Armini, and his bomb detection research team recently granted a series of interviews about the Company's progress in developing an innovative "quantum sniffer" bomb detection device based Implant's proprietary core ion technology.
ADVERTISEMENT
Newsweek Radio
Dr. Armini was asked to comment on bomb detection technology and devices by Newsweek ON AIR as part of a broad overview story on terrorism and homeland security concerns. The program aired Sunday, May 25 and Monday, May 26 at various times on Newsweek's affiliate radio stations.
During the interview, Dr. Armini talked about the portable bomb detection device's advantages over current technology. "Using ion technology, our device senses an explosive such as C4 by an odor as small as 1 part per trillion," Dr. Armini stated. "And because of this method, it could be used to inspect people without touching them." Portability, safety, and adaptability for water contamination and narcotics detection were other advantages of the Quantum sniffer that were covered during the interview.
Anyone who would like to hear the interview can do so by visiting www.newsweek.msnbc.com and clicking on the Newsweek ON AIR link.
Newsweek ON AIR is Newsweek magazine's hour-long news and interview program, broadcast nationwide by more than 100 stations of the AP Radio Network and around the world via Armed Forces Radio and Metro Broadcast in Hong Kong.
Boston Business Journal
Journal staff reporter Tom Witkowski reported how Implant Sciences plans to prosper simultaneously in the medical and security markets. The article details how the company implemented its core ion technology and developed the Quantum Sniffer, which "smells" for airborne particles shed by narcotics, toxic materials and explosives. Dr. Armini notes how the device may provide the company with three-quarters of its business when device is finally deployed to the public. Dr. Armini is also quoted as looking for potential partnerships with X-ray/CT luggage scanning companies who may want to incorporate a bomb detection function in their devices.
Anyone who would like to read the interview may do so by visiting boston.bizjournals.comboston and typing in the keywords, "Implant Sciences."
WRC-TV
Leo Krasnobaev, Implant's Director of Explosives Detection Systems, was interviewed Wednesday, May 21, 2003 by WRC-TV, Washington, DC's NBC affiliate. Dr. Krasnovav's interview appeared on WCR-TV's technology segment, "Digital Edge."
During the interview, Dr. Krasnobaev and his bomb detection team demonstrated the bomb detection device to technology reporter, I.J. Hudson. The physics team also explained how the device can detect most explosives from their scent alone, without wiping off particles and putting them in a machine.
The WRC-TV interview aired Monday night at approximately 5:35 PM with a Nielsen audience of 105,902 households. The interview will also be available on the web (http://www.nbc4.com/technology) and on CD. Anyone who would like to see a copy of the interview on CD may forward his or her request to mailbox@implantsciences.com
About Implant Sciences
Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture, and market products for national security, industry and medicine. Under development is a portable trace explosives detection device for use in identifying explosives, narcotics and other toxic materials, as well as an arsenic measurement and detection device. The Company has received development grants from the US Army, Navy and Air Force, and signed a cooperative R&D agreement with the Transportation Security Administration, the agency which evaluates and approves new equipment for aviation security. Using its proprietary ion implantation and thin film coating technologies, the Company also manufactures and markets radioactive and non-radioactive products for industrial and medical use. Implant Sciences derives revenues from sales of its radioactive seeds used in the treatment of prostate cancer, which are distributed throughout the U.S. by MED-TEC, Inc., a leading manufacturer of equipment and supplies to the radiation oncology community. The Company is also developing brachytherapy products for the treatment of breast and other cancers. Additionally, Implant Sciences modifies the surface characteristics of orthopedic joint implants to reduce polyethylene wear, thereby increasing the life of the implants.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
--------------------------------------------------------------------------------
Contact:
Investor contact:
Implant Sciences Corporation
Anthony Armini, 781/246-0700
aarmini@implantsciences.com
or
David Volpe, 508/523-3141
dvolpe@vcadvisors.com
or
Media contact:
The Investor Relations Group
Kathryn Pfarr or Janet Vasquez
212/825-3210 |
